SlideShare a Scribd company logo
1 of 21
by:




Assessing Immunogenicity and Safety by
High Resolution Monitoring of Cell Mediated
Immunity


  World Vaccine Congress 2008
  CLINICAL TRIALS AND TRIBULATIONS
  08 October 2008, Palais des Congrès de Lyon, France



  Dr. Thomas O. Kleen
  Director, Business and Technology Development
  Cellular Technology Limited (C.T.L.)
  www.immunospot.com                                                                          Homage to Mondrian (1872 -1944)

  The views expressed are those of the author and do not necessarily correspond with the current views of CTL or any regulatory agencies

© Dr. Thomas O. Kleen, Jul-09       CONTACT: Thomas.Kleen@immunospot.com                       C.T.L. CONFIDENTIAL ( www.immunospot.com )   1
by:




 Presentation Outline
 •     Objectives for Immune Monitoring and Biomarker Screening

 •     Rationale for Monitoring Cell Mediated Immunity (CMI)

 •     Current Challenges facing the Broad Implementation of
       Monitoring CMI

 •     Required and Desirable Characteristics of Assays for Monitoring
       CMI in regulated Environments

 •     Assays used to monitor CMI and Cytokines as Biomarkers

 •     ELISPOT Assays Unique Qualification for Cytokine-Based
       Immune Monitoring and Standardization Strategies

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   2
by:




 Company Profile:
 Cellular Technology Limited (C.T.L.)

 •     Founded in 1999

 •     Headquarters and laboratories located in Shaker Heights,
       Ohio, USA

 •     Sales and marketing subsidiaries in Germany and China

 •     Core business areas:
        •    Contract Research Services (CTL Laboratories LLC)
        •    Image Analysis Equipment (CTL Analyzers LLC)

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   3
by:




 Objectives for Immune Monitoring and Biomarker
 Screening during Vaccine Development
 •     Accelerate time to market and save costs:
        •    Potential to add weeks, months or more to a product
             lifecycle under IP protection and/or can allow to enter the
             market ahead of a competing product

 •     Go/no go decisions:
        •    Quickly refocus on alternative approaches if immune
             monitoring data indicate a lack efficacy and/or should
             safety concerns arise during proof of concept, animal
             studies or any clinical phases of development
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   4
by:




 Objectives for Immune Monitoring and Biomarker
 Screening during Vaccine Development (cont)

 •     Delivery of solid comparison data:
        •    Immune monitoring and biomarker screening can be
             implemented during all pre-clinical and clinical phases of
             vaccine development

 •     To increase chances of a successful clinical trial:
        •    High resolution, GLP compliant immune monitoring
             provides regulatory acceptable data



© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   5
by:




 Rationale for Monitoring Cell Mediated Immunity
 during Vaccine Trials

 •     CMI is a critical component during most immunological
       responses; involved in infectious diseases, cancer, and
       autoimmunity

 •     Basic research into correlates of protection has exposed the
       limitations of vaccine approaches that rely solely on antibody
       responses to confer protection against pathogens (e.g., HIV,
       HCV, TB, Smallpox, and more)

 •     The emerging field of therapeutic vaccines has further
       highlighted the need to induce CMI in order to fight cancer, as
       well as atopic or autoimmune diseases

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   6
by:




 Current Challenges facing Broad Implementation
 of CMI Monitoring

 •     Monitoring technologies with sufficient high resolution are
       often perceived to be too costly, complex, and time
       consuming to be routinely utilized with hundreds or even
       thousands of samples. This applies in particular to
       technologies that aim to detect crucial low frequency T-cell
       responses.

 •     Common misconceptions surrounding regulatory
       acceptance of CMI and biomarker data have to be
       overcome.
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   7
by:




 Current Challenges facing Broad Implementation
 of CMI Monitoring (cont)

 •     Limited awareness exists in certain segments of the
       industry regarding recent advances in:
        •    Cell sample cryo-preservation and thawing procedures
        •    Cost effective, sensitive, single cell-based, high
             throughput capable assay technologies
        •    Validation procedures for cell-based assay systems
        •    Standardization reagents and procedures for cell-based
             assay and test systems


© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   8
by:




 Required Characteristics of Assays to Monitor
 CMI in Regulated Environments
 •     Measures a physiological and clinically relevant response

 •     Is a reproducible, reliable assay for testing serial samples

 •     Lends itself to validation (possibility of determining, e.g.,
       Accuracy, Precision, Specificity, Linearity, Limits of Detection)

 •     Has a meaningful sensitivity that is able to detect low frequency
       cells (Memory T-cells are frequently rare as 1 in 100,000 or less)

 •     Available data analysis equipment must be able to be integrated
       in 21 CFR Part 11 compliant laboratory settings (i.e., system
       validation, computer generated audit trails)
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   9
by:




 Desirable Features of Assays for Monitoring CMI
 in Regulated Environments
 •     Performs identical with fresh and previously frozen samples

 •     Can be standardized; to enable, for example, inter-study
       comparisons to make data more robust for multicenter or large
       clinical trials

 •     Uses the least amount of cells and clinical sample material

 •     Capability to be run in high throughput mode to accommodate
       large-volume testing with hundreds of samples a day

 •     Availability of automated, high throughput capable data read-out
       equipment including data analysis software to insure objectivity
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   10
by:




 Commonly Available Assay Technologies to
 Evaluate Cytokine Production and CMI

 •     Enzyme-Linked Immunosorbent Assay (ELISA)
                                                                                          Supernatant based
 •     Cytometric Bead Array (CBA)

 •     Fluorescence-Activated Cell Sorter (FACS)
                • Intracytoplasmatic Cytokine Staining (ICS)
                • Tetramer staining
                • Pentamer staining                                                       Single Cell based

                • Surface marker staining
 •     Enzyme-Linked Immunospot Assay (ELISPOT)

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   11
by:




 Advantage of Using Single Cell Cytokine
 Secretion by T-cells as Biomarker

 •     Establish the quality of an immune response, i.e., the type of
       products T-cells secrete in response to a vaccine candidate,
       allowing the differentiation between Th1/Th2/Th17 (CD4+ T-cells)
       and Tc1/Tc2 (CD8+ T-cells) based on cytokine signatures

 •     Establish the quantity (amount) of the secreted cytokine product
       in response to an antigen or vaccine

 •     Establish the frequency (clonal sizes) of the responding cells to
       an antigen or vaccine, giving an indication about scale or
       potency of the immune response (or adverse effects)

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   12
by:




    ELISPOT Assay’s Unique Qualification for
    Cytokine-Based Immune Monitoring
•    Sensitivity: Routine detection limits of 1 in                                                               100.00




                                                                                        % IFN-γ positive cells
                                                                                                                            FACS
                                                                                                                 10.00

     500,000, or better. That is several ten to                                                                   1.00

                                                                                                                  0.10
     hundred folds more sensitive than ELISA, CBA,                                                                0.01

     ICS, Tetramer, etc.                                                                                           0.8
                                                                                                                        101    102    103    104    105   106

                                                                                                                            ELISA
                                                                                                                   0.6




                                                                                        OD405
•    Direct ex vivo cell frequencies: Measures the
                                                                                                                   0.4

                                                                                                                   0.2

                                                                                                                   0.0
     physiologic magnitude of T-cell immunity, with                                                                     101     102     103        104    105




                                                                                        # of IFN-γ Spots/Well
     no need for in vitro expansion (not provided by                                                              500
                                                                                                                  400
                                                                                                                            ELISPOT

     ELISA, CBA, *ICSlow, *Tetramerlow, etc.)                                                                     300
                                                                                                                  200
                                                                                                                  100


•    Samples not pharmacologically treated: No use
                                                                                                                    0
                                                                                                                        0     100 200 300 400 500 600
                                                                                                                                Number of Cells

     of secretion inhibitors or cell permeable agents
     as with ICS and FACS               *(only applies to low frequency T cell responses)
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )                                               13
by:




    ELISPOT Assay’s Unique Qualification for
    Cytokine-Based Immune Monitoring (cont)

•    Robustness: Cell samples can be
                                                                       IFN-g                    IL-2
     freeze thawed while maintaining
     highly reproducible results

•    Validation Capabilities: Assays
                                                                       IL-4                     IL-5
     can be validated under GLP with
     multiple cytokines and test
     systems (e.g., CTL Laboratories
     has validated for its clients
                                                                   Performance Fresh versus frozen PBMC in
     human, mouse, monkey, and pig                                 J. Immunol. Methods, 2003, 278 :79– 93
     test systems, among others)

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com      C.T.L. CONFIDENTIAL ( www.immunospot.com )   14
by:




    ELISPOT Assay’s Unique Qualification for
    Cytokine-Based Immune Monitoring (cont.)
•    Scalable high throughput capability: In trained and appropriately
     setup up laboratory environments, up to 450 clinical samples can
     be tested per week (e.g., CTL Laboratories tested 10,000
     individual samples in less then 6 months)

•    21 CFR Part 11 integration enabled equipment: For example,
     CTL Analyzer’s line of ImmunoSpot® ELISPOT analysis
     equipment and software solutions, which are designed to be
     integrated into Part 11 compliant laboratory settings

•    Possibilities of standardization: Starting from methods and
     reagents for clinical sample preservation to final data read-outs,
     implementation of assay standardization is feasible
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   15
by:




 Standardization Strategies for CMI monitoring
 and ELISPOT
 •     Harmonize sample collection at clinical sites
        •    Training and qualification of all clinical sites in proper sample
             handling, PBMC processing, cryopreservation and shipping
             standard operating procedures (SOPs)

 •     Harmonize methods across all participating laboratories
        •    Implementation of detailed SOPs for cell thawing, cell
             counting, assay procedures and the analysis of assay results
        •    Standardize all assay materials, including plates, antibodies,
             media and enzymes (always re-qualify new lots!)
        •    Utilize cell-based reference sample PBMC to optimize assays
             and compare performance between laboratories
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   16
by:




 Advantages of serum-free cryopreservation
 reagents and assay media
 •     Use of standardized serum-free cryopreservation reagents for
       PBMC yields a <95% post-thaw viability, maximizing clinical
       sample utilization (in combination with optimized freeze-thaw
       procedures)
 •     Serum-containing undefined products like Fetal Bovine Serum
       (FBS), Fetal Calf Serum (FCS), as well as human ABO serum in
       cryo-preservation and assay media can cause significant assay
       background noise and artifacts rooted in large intra-batch and
       performance variations
 •     Utilization of bovine products is prohibitive for all clinical trials
       involving international shipping of samples, based on strict import
       restrictions of many countries due to BSE concerns (mad cow
       disease)
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   17
by:




 Use of cryo-preserved reference sample PBMC
•    Reference PBMC library of 40 healthy, HLA-typed and immune-
     characterized individuals with up to 10 billion cells per individual
•    Each sample has an established cytokine secretory reactivity to 32
     individual T cell peptide epitopes of Cytomegalo-, Epstein-Barr,
     and Flu virus (CEF), as well as to 5 proteins from Candida, Dust
     Mite, Mumps, Tetanus, and PPD
•    Used for assay validation and protocol development through
     authentic, physilogical relevant cell activities without need for
     artifical, artifact prone mitogenic stimulation (PHA. ConA)
•    Enables realistic benchmarking of laboratory perfomance and
     internal controls during clinical trials without scarifcing precious
     clinical samples
© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   18
by:




ELISPOT as Validated Cellular Readout of a Functional Assay
                                                       96 well mircotiter plate coated with
    A                                                  detection antibody

                                                       Secreting cell – e.g., antigen-stimulated
    B                                                  T cell secreting cytokine

                                                       Plate-bound secretory product
    C
                                                       (cytokine) after cells are washed away

                                                       Product-specific detection antibody with
    D
                                                       linked enzyme

                                                       Enzyme catalyzed chromogen spot
    E
                                                       development or fluorescence label

          PVDF-membrane             Antigen-stimulated cell       Enzyme-coupled detection antibody

         Secreted cytokine          Capture antibody             Chromogen/Fluorescence label

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com         C.T.L. CONFIDENTIAL ( www.immunospot.com )   19
by:




 Validated Computer Assisted Image Acquisition,
 Counting and Analysis of Data




© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   20
by:




                                Thank You!

                                   Questions?

© Dr. Thomas O. Kleen, Jul-09   CONTACT: Thomas.Kleen@immunospot.com   C.T.L. CONFIDENTIAL ( www.immunospot.com )   21

More Related Content

Viewers also liked

Nanobiotec luminex assay
Nanobiotec luminex assayNanobiotec luminex assay
Nanobiotec luminex assayNANOBIOTEC LLC
 
Elevating Elispot To An Exact Science
Elevating Elispot To An Exact ScienceElevating Elispot To An Exact Science
Elevating Elispot To An Exact Scienceikoppandi
 
Reference Pbmc
Reference PbmcReference Pbmc
Reference Pbmcikoppandi
 
Isolating Primary Cells 101
Isolating Primary Cells 101Isolating Primary Cells 101
Isolating Primary Cells 101allcells
 
La respirazione cellulare
La respirazione cellulareLa respirazione cellulare
La respirazione cellulareMartina iorio
 
ELISA Vs ELISPOT - Principle, Procedure, Advantages
ELISA Vs ELISPOT - Principle, Procedure, AdvantagesELISA Vs ELISPOT - Principle, Procedure, Advantages
ELISA Vs ELISPOT - Principle, Procedure, Advantagesajithnandanam
 

Viewers also liked (9)

Nanobiotec luminex assay
Nanobiotec luminex assayNanobiotec luminex assay
Nanobiotec luminex assay
 
Elevating Elispot To An Exact Science
Elevating Elispot To An Exact ScienceElevating Elispot To An Exact Science
Elevating Elispot To An Exact Science
 
PBMC Presentation, Prague, December 2014
PBMC Presentation, Prague, December 2014PBMC Presentation, Prague, December 2014
PBMC Presentation, Prague, December 2014
 
Reference Pbmc
Reference PbmcReference Pbmc
Reference Pbmc
 
Isolating Primary Cells 101
Isolating Primary Cells 101Isolating Primary Cells 101
Isolating Primary Cells 101
 
La respirazione cellulare
La respirazione cellulareLa respirazione cellulare
La respirazione cellulare
 
ELISA Vs ELISPOT - Principle, Procedure, Advantages
ELISA Vs ELISPOT - Principle, Procedure, AdvantagesELISA Vs ELISPOT - Principle, Procedure, Advantages
ELISA Vs ELISPOT - Principle, Procedure, Advantages
 
Isolation of pbmc
Isolation of pbmcIsolation of pbmc
Isolation of pbmc
 
Glicolisi
GlicolisiGlicolisi
Glicolisi
 

Similar to Invited Presentation at the World Vaccine Congress Lyon 2008

Featured Presentation FIRN Kona 2009
Featured Presentation FIRN Kona 2009Featured Presentation FIRN Kona 2009
Featured Presentation FIRN Kona 2009TOKBLS
 
SMi Group's Immunogenicity conference
SMi Group's Immunogenicity conferenceSMi Group's Immunogenicity conference
SMi Group's Immunogenicity conferenceDale Butler
 
Immune Monitoring
Immune MonitoringImmune Monitoring
Immune MonitoringPamoja
 
SMi Group's Cancer Vaccines
SMi Group's Cancer VaccinesSMi Group's Cancer Vaccines
SMi Group's Cancer VaccinesDale Butler
 
The Life-Changing Impact of AI in Healthcare
The Life-Changing Impact of AI in HealthcareThe Life-Changing Impact of AI in Healthcare
The Life-Changing Impact of AI in HealthcareKalin Hitrov
 
Discovering New Innovations in Oncology
Discovering New Innovations in OncologyDiscovering New Innovations in Oncology
Discovering New Innovations in OncologyInsideScientific
 
WP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final editsWP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final editsChris Learn, Ph.D, PMP
 
Introduction to cancer vaccines
Introduction to cancer vaccinesIntroduction to cancer vaccines
Introduction to cancer vaccinesZeena Nackerdien
 
ImmunoCellular Company presentation
ImmunoCellular Company presentationImmunoCellular Company presentation
ImmunoCellular Company presentationguest11f678
 
P-144_Immunogenicity
P-144_ImmunogenicityP-144_Immunogenicity
P-144_ImmunogenicityJames Bell
 
Advances in immunotherapy for lymphomas and myelomas
Advances in immunotherapy for lymphomas and myelomasAdvances in immunotherapy for lymphomas and myelomas
Advances in immunotherapy for lymphomas and myelomasspa718
 
Advances in immunotherapy for lymphomas and myeloma
Advances in immunotherapy for lymphomas and myelomaAdvances in immunotherapy for lymphomas and myeloma
Advances in immunotherapy for lymphomas and myelomaspa718
 
Immuno-oncology Discoveries, University of Chicago
Immuno-oncology Discoveries, University of ChicagoImmuno-oncology Discoveries, University of Chicago
Immuno-oncology Discoveries, University of Chicagouchicagotech
 
SMi Group's Cancer Vaccines 2015 conference
SMi Group's Cancer Vaccines 2015 conferenceSMi Group's Cancer Vaccines 2015 conference
SMi Group's Cancer Vaccines 2015 conferenceDale Butler
 
Cancer vaccines 20_july2020
Cancer vaccines 20_july2020Cancer vaccines 20_july2020
Cancer vaccines 20_july2020Zeena Nackerdien
 

Similar to Invited Presentation at the World Vaccine Congress Lyon 2008 (20)

Featured Presentation FIRN Kona 2009
Featured Presentation FIRN Kona 2009Featured Presentation FIRN Kona 2009
Featured Presentation FIRN Kona 2009
 
SMi Group's Immunogenicity conference
SMi Group's Immunogenicity conferenceSMi Group's Immunogenicity conference
SMi Group's Immunogenicity conference
 
Immune Monitoring
Immune MonitoringImmune Monitoring
Immune Monitoring
 
SMi Group's Cancer Vaccines
SMi Group's Cancer VaccinesSMi Group's Cancer Vaccines
SMi Group's Cancer Vaccines
 
Liverpool uemseflm2014
Liverpool uemseflm2014Liverpool uemseflm2014
Liverpool uemseflm2014
 
The Life-Changing Impact of AI in Healthcare
The Life-Changing Impact of AI in HealthcareThe Life-Changing Impact of AI in Healthcare
The Life-Changing Impact of AI in Healthcare
 
Discovering New Innovations in Oncology
Discovering New Innovations in OncologyDiscovering New Innovations in Oncology
Discovering New Innovations in Oncology
 
WP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final editsWP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final edits
 
Introduction to cancer vaccines
Introduction to cancer vaccinesIntroduction to cancer vaccines
Introduction to cancer vaccines
 
Imugene (ASX: IMU)
Imugene (ASX: IMU)Imugene (ASX: IMU)
Imugene (ASX: IMU)
 
ImmunoCellular Company presentation
ImmunoCellular Company presentationImmunoCellular Company presentation
ImmunoCellular Company presentation
 
P-144_Immunogenicity
P-144_ImmunogenicityP-144_Immunogenicity
P-144_Immunogenicity
 
Advances in immunotherapy for lymphomas and myelomas
Advances in immunotherapy for lymphomas and myelomasAdvances in immunotherapy for lymphomas and myelomas
Advances in immunotherapy for lymphomas and myelomas
 
Advances in immunotherapy for lymphomas and myeloma
Advances in immunotherapy for lymphomas and myelomaAdvances in immunotherapy for lymphomas and myeloma
Advances in immunotherapy for lymphomas and myeloma
 
tumor immunity
tumor immunitytumor immunity
tumor immunity
 
Immuron Presentation
Immuron PresentationImmuron Presentation
Immuron Presentation
 
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)
 
Immuno-oncology Discoveries, University of Chicago
Immuno-oncology Discoveries, University of ChicagoImmuno-oncology Discoveries, University of Chicago
Immuno-oncology Discoveries, University of Chicago
 
SMi Group's Cancer Vaccines 2015 conference
SMi Group's Cancer Vaccines 2015 conferenceSMi Group's Cancer Vaccines 2015 conference
SMi Group's Cancer Vaccines 2015 conference
 
Cancer vaccines 20_july2020
Cancer vaccines 20_july2020Cancer vaccines 20_july2020
Cancer vaccines 20_july2020
 

Invited Presentation at the World Vaccine Congress Lyon 2008

  • 1. by: Assessing Immunogenicity and Safety by High Resolution Monitoring of Cell Mediated Immunity World Vaccine Congress 2008 CLINICAL TRIALS AND TRIBULATIONS 08 October 2008, Palais des Congrès de Lyon, France Dr. Thomas O. Kleen Director, Business and Technology Development Cellular Technology Limited (C.T.L.) www.immunospot.com Homage to Mondrian (1872 -1944) The views expressed are those of the author and do not necessarily correspond with the current views of CTL or any regulatory agencies © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 1
  • 2. by: Presentation Outline • Objectives for Immune Monitoring and Biomarker Screening • Rationale for Monitoring Cell Mediated Immunity (CMI) • Current Challenges facing the Broad Implementation of Monitoring CMI • Required and Desirable Characteristics of Assays for Monitoring CMI in regulated Environments • Assays used to monitor CMI and Cytokines as Biomarkers • ELISPOT Assays Unique Qualification for Cytokine-Based Immune Monitoring and Standardization Strategies © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 2
  • 3. by: Company Profile: Cellular Technology Limited (C.T.L.) • Founded in 1999 • Headquarters and laboratories located in Shaker Heights, Ohio, USA • Sales and marketing subsidiaries in Germany and China • Core business areas: • Contract Research Services (CTL Laboratories LLC) • Image Analysis Equipment (CTL Analyzers LLC) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 3
  • 4. by: Objectives for Immune Monitoring and Biomarker Screening during Vaccine Development • Accelerate time to market and save costs: • Potential to add weeks, months or more to a product lifecycle under IP protection and/or can allow to enter the market ahead of a competing product • Go/no go decisions: • Quickly refocus on alternative approaches if immune monitoring data indicate a lack efficacy and/or should safety concerns arise during proof of concept, animal studies or any clinical phases of development © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 4
  • 5. by: Objectives for Immune Monitoring and Biomarker Screening during Vaccine Development (cont) • Delivery of solid comparison data: • Immune monitoring and biomarker screening can be implemented during all pre-clinical and clinical phases of vaccine development • To increase chances of a successful clinical trial: • High resolution, GLP compliant immune monitoring provides regulatory acceptable data © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 5
  • 6. by: Rationale for Monitoring Cell Mediated Immunity during Vaccine Trials • CMI is a critical component during most immunological responses; involved in infectious diseases, cancer, and autoimmunity • Basic research into correlates of protection has exposed the limitations of vaccine approaches that rely solely on antibody responses to confer protection against pathogens (e.g., HIV, HCV, TB, Smallpox, and more) • The emerging field of therapeutic vaccines has further highlighted the need to induce CMI in order to fight cancer, as well as atopic or autoimmune diseases © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 6
  • 7. by: Current Challenges facing Broad Implementation of CMI Monitoring • Monitoring technologies with sufficient high resolution are often perceived to be too costly, complex, and time consuming to be routinely utilized with hundreds or even thousands of samples. This applies in particular to technologies that aim to detect crucial low frequency T-cell responses. • Common misconceptions surrounding regulatory acceptance of CMI and biomarker data have to be overcome. © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 7
  • 8. by: Current Challenges facing Broad Implementation of CMI Monitoring (cont) • Limited awareness exists in certain segments of the industry regarding recent advances in: • Cell sample cryo-preservation and thawing procedures • Cost effective, sensitive, single cell-based, high throughput capable assay technologies • Validation procedures for cell-based assay systems • Standardization reagents and procedures for cell-based assay and test systems © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 8
  • 9. by: Required Characteristics of Assays to Monitor CMI in Regulated Environments • Measures a physiological and clinically relevant response • Is a reproducible, reliable assay for testing serial samples • Lends itself to validation (possibility of determining, e.g., Accuracy, Precision, Specificity, Linearity, Limits of Detection) • Has a meaningful sensitivity that is able to detect low frequency cells (Memory T-cells are frequently rare as 1 in 100,000 or less) • Available data analysis equipment must be able to be integrated in 21 CFR Part 11 compliant laboratory settings (i.e., system validation, computer generated audit trails) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 9
  • 10. by: Desirable Features of Assays for Monitoring CMI in Regulated Environments • Performs identical with fresh and previously frozen samples • Can be standardized; to enable, for example, inter-study comparisons to make data more robust for multicenter or large clinical trials • Uses the least amount of cells and clinical sample material • Capability to be run in high throughput mode to accommodate large-volume testing with hundreds of samples a day • Availability of automated, high throughput capable data read-out equipment including data analysis software to insure objectivity © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 10
  • 11. by: Commonly Available Assay Technologies to Evaluate Cytokine Production and CMI • Enzyme-Linked Immunosorbent Assay (ELISA) Supernatant based • Cytometric Bead Array (CBA) • Fluorescence-Activated Cell Sorter (FACS) • Intracytoplasmatic Cytokine Staining (ICS) • Tetramer staining • Pentamer staining Single Cell based • Surface marker staining • Enzyme-Linked Immunospot Assay (ELISPOT) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 11
  • 12. by: Advantage of Using Single Cell Cytokine Secretion by T-cells as Biomarker • Establish the quality of an immune response, i.e., the type of products T-cells secrete in response to a vaccine candidate, allowing the differentiation between Th1/Th2/Th17 (CD4+ T-cells) and Tc1/Tc2 (CD8+ T-cells) based on cytokine signatures • Establish the quantity (amount) of the secreted cytokine product in response to an antigen or vaccine • Establish the frequency (clonal sizes) of the responding cells to an antigen or vaccine, giving an indication about scale or potency of the immune response (or adverse effects) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 12
  • 13. by: ELISPOT Assay’s Unique Qualification for Cytokine-Based Immune Monitoring • Sensitivity: Routine detection limits of 1 in 100.00 % IFN-γ positive cells FACS 10.00 500,000, or better. That is several ten to 1.00 0.10 hundred folds more sensitive than ELISA, CBA, 0.01 ICS, Tetramer, etc. 0.8 101 102 103 104 105 106 ELISA 0.6 OD405 • Direct ex vivo cell frequencies: Measures the 0.4 0.2 0.0 physiologic magnitude of T-cell immunity, with 101 102 103 104 105 # of IFN-γ Spots/Well no need for in vitro expansion (not provided by 500 400 ELISPOT ELISA, CBA, *ICSlow, *Tetramerlow, etc.) 300 200 100 • Samples not pharmacologically treated: No use 0 0 100 200 300 400 500 600 Number of Cells of secretion inhibitors or cell permeable agents as with ICS and FACS *(only applies to low frequency T cell responses) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 13
  • 14. by: ELISPOT Assay’s Unique Qualification for Cytokine-Based Immune Monitoring (cont) • Robustness: Cell samples can be IFN-g IL-2 freeze thawed while maintaining highly reproducible results • Validation Capabilities: Assays IL-4 IL-5 can be validated under GLP with multiple cytokines and test systems (e.g., CTL Laboratories has validated for its clients Performance Fresh versus frozen PBMC in human, mouse, monkey, and pig J. Immunol. Methods, 2003, 278 :79– 93 test systems, among others) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 14
  • 15. by: ELISPOT Assay’s Unique Qualification for Cytokine-Based Immune Monitoring (cont.) • Scalable high throughput capability: In trained and appropriately setup up laboratory environments, up to 450 clinical samples can be tested per week (e.g., CTL Laboratories tested 10,000 individual samples in less then 6 months) • 21 CFR Part 11 integration enabled equipment: For example, CTL Analyzer’s line of ImmunoSpot® ELISPOT analysis equipment and software solutions, which are designed to be integrated into Part 11 compliant laboratory settings • Possibilities of standardization: Starting from methods and reagents for clinical sample preservation to final data read-outs, implementation of assay standardization is feasible © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 15
  • 16. by: Standardization Strategies for CMI monitoring and ELISPOT • Harmonize sample collection at clinical sites • Training and qualification of all clinical sites in proper sample handling, PBMC processing, cryopreservation and shipping standard operating procedures (SOPs) • Harmonize methods across all participating laboratories • Implementation of detailed SOPs for cell thawing, cell counting, assay procedures and the analysis of assay results • Standardize all assay materials, including plates, antibodies, media and enzymes (always re-qualify new lots!) • Utilize cell-based reference sample PBMC to optimize assays and compare performance between laboratories © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 16
  • 17. by: Advantages of serum-free cryopreservation reagents and assay media • Use of standardized serum-free cryopreservation reagents for PBMC yields a <95% post-thaw viability, maximizing clinical sample utilization (in combination with optimized freeze-thaw procedures) • Serum-containing undefined products like Fetal Bovine Serum (FBS), Fetal Calf Serum (FCS), as well as human ABO serum in cryo-preservation and assay media can cause significant assay background noise and artifacts rooted in large intra-batch and performance variations • Utilization of bovine products is prohibitive for all clinical trials involving international shipping of samples, based on strict import restrictions of many countries due to BSE concerns (mad cow disease) © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 17
  • 18. by: Use of cryo-preserved reference sample PBMC • Reference PBMC library of 40 healthy, HLA-typed and immune- characterized individuals with up to 10 billion cells per individual • Each sample has an established cytokine secretory reactivity to 32 individual T cell peptide epitopes of Cytomegalo-, Epstein-Barr, and Flu virus (CEF), as well as to 5 proteins from Candida, Dust Mite, Mumps, Tetanus, and PPD • Used for assay validation and protocol development through authentic, physilogical relevant cell activities without need for artifical, artifact prone mitogenic stimulation (PHA. ConA) • Enables realistic benchmarking of laboratory perfomance and internal controls during clinical trials without scarifcing precious clinical samples © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 18
  • 19. by: ELISPOT as Validated Cellular Readout of a Functional Assay 96 well mircotiter plate coated with A detection antibody Secreting cell – e.g., antigen-stimulated B T cell secreting cytokine Plate-bound secretory product C (cytokine) after cells are washed away Product-specific detection antibody with D linked enzyme Enzyme catalyzed chromogen spot E development or fluorescence label PVDF-membrane Antigen-stimulated cell Enzyme-coupled detection antibody Secreted cytokine Capture antibody Chromogen/Fluorescence label © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 19
  • 20. by: Validated Computer Assisted Image Acquisition, Counting and Analysis of Data © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 20
  • 21. by: Thank You! Questions? © Dr. Thomas O. Kleen, Jul-09 CONTACT: Thomas.Kleen@immunospot.com C.T.L. CONFIDENTIAL ( www.immunospot.com ) 21